Download PDF
Semin Reprod Med 2011; 29(4): 317-327
DOI: 10.1055/s-0031-1280917
© Thieme Medical Publishers

Bone Health in Primary Ovarian Insufficiency

Rose Marino1 , Madhusmita Misra1 , 2
  • 1Pediatric Endocrine Unit, at Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
  • 2Neuroendocrine Unit, at Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Further Information

Publication History

Publication Date:
03 October 2011 (online)

    Permissions and Reprints

ABSTRACT

The etiology of primary ovarian insufficiency (POI) may be genetic, autoimmune, or iatrogenic. Genetic conditions include 45,X, 46,XX and 46,XY POI, and POI associated with galactosemia and FMR premutations. Women with autoimmune polyglandular syndromes 1 and 2 may develop autoimmune POI, as may those who receive chemotherapy or radiotherapy. Hypogonadism in POI can result in reduced rates of bone mass accrual in adolescents and young women, and low bone density for age in older women. Measures to optimize bone density in women with POI include attention to lifestyle measures and hormone replacement. Resistance training and adequate calcium and vitamin D supplementation are essential, as is replacement of estrogen/progestin. Estrogen/progestin replacement may be problematic in women with estrogen-sensitive breast cancer who developed POI in the course of therapy for cancer. In these instances, bisphosphonates are an option. In particular, zoledronic acid has been used successfully in conjunction with chemotherapy, tamoxifen, and aromatase inhibitors.

KEYWORDS

Bone density - bone microarchitecture - bone turnover - estrogen - androgens - bisphosphonates

REFERENCES

  • 1 Nelson L M. Clinical practice. Primary ovarian insufficiency.  N Engl J Med. 2009;  360 (6) 606-614
    CrossrefPubMedSearch in Google Scholar
  • 2 Ohlsson C, Bengtsson B A, Isaksson O G, Andreassen T T, Slootweg M C. Growth hormone and bone.  Endocr Rev. 1998;  19 (1) 55-79
    CrossrefPubMedSearch in Google Scholar
  • 3 Bachrach L K. Acquisition of optimal bone mass in childhood and adolescence.  Trends Endocrinol Metab. 2001;  12 (1) 22-28
    CrossrefPubMedSearch in Google Scholar
  • 4 Miller K K, Biller B M, Beauregard C et al.. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.  J Clin Endocrinol Metab. 2006;  91 (5) 1683-1690
    CrossrefPubMedSearch in Google Scholar
  • 5 Francucci C M, Romagni P, Camilletti A et al.. Effect of natural early menopause on bone mineral density.  Maturitas. 2008;  59 (4) 323-328
    CrossrefPubMedSearch in Google Scholar
  • 6 Gallagher J C. Effect of early menopause on bone mineral density and fractures.  Menopause. 2007;  14 (3 Pt 2) 567-571
    CrossrefPubMedSearch in Google Scholar
  • 7 Patel R, Blake G M, Fogelman I. Peripheral and central measurements of bone mineral density are equally strongly associated with clinical risk factors for osteoporosis.  Calcif Tissue Int. 2007;  80 (2) 89-96
    CrossrefPubMedSearch in Google Scholar
  • 8 Bachelot A, Rouxel A, Massin N POF-GIS Study Group et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure.  Eur J Endocrinol. 2009;  161 (1) 179-187
    CrossrefPubMedSearch in Google Scholar
  • 9 Uygur D, Sengül O, Bayar D, Erdinç S, Batioğlu S, Mollamahmutoglu L. Bone loss in young women with premature ovarian failure.  Arch Gynecol Obstet. 2005;  273 (1) 17-19
    CrossrefPubMedSearch in Google Scholar
  • 10 Popat V B, Calis K A, Vanderhoof V H et al.. Bone mineral density in estrogen-deficient young women.  J Clin Endocrinol Metab. 2009;  94 (7) 2277-2283
    CrossrefPubMedSearch in Google Scholar
  • 11 Leite-Silva P, Bedone A, Pinto-Neto A M, Costa J V, Costa-Paiva L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure.  Arch Gynecol Obstet. 2009;  280 (2) 177-181
    CrossrefPubMedSearch in Google Scholar
  • 12 Holroyd C R, Davies J H, Taylor P et al.. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome.  Osteoporos Int. 2010;  21 (12) 2093-2099
    CrossrefPubMedSearch in Google Scholar
  • 13 Bakalov V K, Chen M L, Baron J et al.. Bone mineral density and fractures in Turner syndrome.  Am J Med. 2003;  115 (4) 259-264
    CrossrefPubMedSearch in Google Scholar
  • 14 Costa A M, Lemos-Marini S H, Baptista M T, Morcillo A M, Maciel-Guerra A T, Guerra Jr G. Bone mineralization in Turner syndrome: a transverse study of the determinant factors in 58 patients.  J Bone Miner Metab. 2002;  20 (5) 294-297
    CrossrefPubMedSearch in Google Scholar
  • 15 Gravholt C H, Lauridsen A L, Brixen K, Mosekilde L, Heickendorff L, Christiansen J S. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study.  J Clin Endocrinol Metab. 2002;  87 (6) 2798-2808
    CrossrefPubMedSearch in Google Scholar
  • 16 Buzi F, Maccarinelli G, Guaragni B et al.. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.  Clin Endocrinol (Oxf). 2004;  60 (1) 87-91
    CrossrefPubMedSearch in Google Scholar
  • 17 Nissen N, Gravholt C H, Abrahamsen B et al.. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study.  Clin Endocrinol (Oxf). 2007;  67 (6) 897-903
    CrossrefPubMedSearch in Google Scholar
  • 18 Bakalov V K, Bondy C A. Fracture risk and bone mineral density in Turner syndrome.  Rev Endocr Metab Disord. 2008;  9 (2) 145-151
    CrossrefPubMedSearch in Google Scholar
  • 19 Bakalov V K, Axelrod L, Baron J et al.. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency.  J Clin Endocrinol Metab. 2003;  88 (12) 5717-5722
    CrossrefPubMedSearch in Google Scholar
  • 20 Gravholt C H, Vestergaard P, Hermann A P, Mosekilde L, Brixen K, Christiansen J S. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey.  Clin Endocrinol (Oxf). 2003;  59 (1) 89-96
    CrossrefPubMedSearch in Google Scholar
  • 21 Zuckerman-Levin N, Yaniv I, Schwartz T, Guttmann H, Hochberg Z. Normal DXA bone mineral density but frail cortical bone in Turner's syndrome.  Clin Endocrinol (Oxf). 2007;  67 (1) 60-64
    CrossrefPubMedSearch in Google Scholar
  • 22 Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome—importance of growth promoting and oestrogen therapy.  Clin Endocrinol (Oxf). 1999;  51 (4) 497-502
    CrossrefPubMedSearch in Google Scholar
  • 23 Han T S, Cadge B, Conway G S. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner's syndrome.  Clin Endocrinol (Oxf). 2006;  65 (5) 643-647
    CrossrefPubMedSearch in Google Scholar
  • 24 Michala L, Goswami D, Creighton S M, Conway G S. Swyer syndrome: presentation and outcomes.  BJOG. 2008;  115 (6) 737-741
    CrossrefPubMedSearch in Google Scholar
  • 25 Benetti-Pinto C L, Bedone A, Magna L A, Marques-Neto J F. Factors associated with the reduction of bone density in patients with gonadal dysgenesis.  Fertil Steril. 2002;  77 (3) 571-575
    CrossrefPubMedSearch in Google Scholar
  • 26 Han T S, Goswami D, Trikudanathan S, Creighton S M, Conway G S. Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis.  Eur J Endocrinol. 2008;  159 (2) 179-185
    CrossrefPubMedSearch in Google Scholar
  • 27 Allen E G, Sullivan A K, Marcus M et al.. Examination of reproductive aging milestones among women who carry the FMR1 premutation.  Hum Reprod. 2007;  22 (8) 2142-2152
    CrossrefPubMedSearch in Google Scholar
  • 28 Panis B, Forget P P, van Kroonenburgh M J et al.. Bone metabolism in galactosemia.  Bone. 2004;  35 (4) 982-987
    CrossrefPubMedSearch in Google Scholar
  • 29 Berry G T. Galactosemia and amenorrhea in the adolescent.  Ann N Y Acad Sci. 2008;  1135 112-117
    CrossrefPubMedSearch in Google Scholar
  • 30 Kaufman F R, Loro M L, Azen C, Wenz E, Gilsanz V. Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia.  J Pediatr. 1993;  123 (3) 365-370
    CrossrefPubMedSearch in Google Scholar
  • 31 Rubio-Gozalbo M E, Hamming S, van Kroonenburgh M J, Bakker J A, Vermeer C, Forget P P. Bone mineral density in patients with classic galactosaemia.  Arch Dis Child. 2002;  87 (1) 57-60
    CrossrefPubMedSearch in Google Scholar
  • 32 Molina J R, Barton D L, Loprinzi C L. Chemotherapy-induced ovarian failure: manifestations and management.  Drug Saf. 2005;  28 (5) 401-416
    CrossrefPubMedSearch in Google Scholar
  • 33 Bines J, Oleske D M, Cobleigh M A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.  J Clin Oncol. 1996;  14 (5) 1718-1729
    PubMedSearch in Google Scholar
  • 34 Bruning P F, Pit M J, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.  Br J Cancer. 1990;  61 (2) 308-310
    CrossrefPubMedSearch in Google Scholar
  • 35 Hadji P, Ziller M, Maskow C, Albert U, Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.  Eur J Cancer. 2009;  45 (18) 3205-3212
    CrossrefPubMedSearch in Google Scholar
  • 36 Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.  Br J Cancer. 1997;  75 (2) 301-305
    CrossrefPubMedSearch in Google Scholar
  • 37 Tham Y L, Sexton K, Weiss H L, Elledge R M, Friedman L C, Kramer R M. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.  J Support Oncol. 2006;  4 (6) 295-298 304
    PubMedSearch in Google Scholar
  • 38 McCune W J, Saluja M, Bhat S, Lange L A, Holzman L, Johnson K. Correlation of membranous glomerular ultrastructural changes with disease severity and outcome in lupus patients initiating cyclophosphamide therapy.  Lupus. 2005;  14 (6) 426-433
    CrossrefPubMedSearch in Google Scholar
  • 39 Davies J H, Evans B A, Jenney M E, Gregory J W. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy.  Bone. 2002;  31 (2) 319-326
    CrossrefPubMedSearch in Google Scholar
  • 40 Kanis J A, McCloskey E V, Powles T, Paterson A H, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer.  Br J Cancer. 1999;  79 (7-8) 1179-1181
    CrossrefPubMedSearch in Google Scholar
  • 41 Headley J A, Theriault R L, LeBlanc A D, Vassilopoulou-Sellin R, Hortobagyi G N. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy.  Cancer Invest. 1998;  16 (1) 6-11
    CrossrefPubMedSearch in Google Scholar
  • 42 Powles T J, McCloskey E, Paterson A H et al.. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.  J Natl Cancer Inst. 1998;  90 (9) 704-708
    CrossrefPubMedSearch in Google Scholar
  • 43 Pfeilschifter J, Diel I J. Osteoporosis due to cancer treatment: pathogenesis and management.  J Clin Oncol. 2000;  18 (7) 1570-1593
    PubMedSearch in Google Scholar
  • 44 Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.  J Clin Oncol. 2006;  24 (4) 675-680
    CrossrefPubMedSearch in Google Scholar
  • 45 Imai A, Furui T. Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues.  J Obstet Gynaecol. 2007;  27 (1) 20-24
    CrossrefPubMedSearch in Google Scholar
  • 46 Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe J M. Fertility after treatment for Hodgkin's disease.  Ann Oncol. 2002;  13 (Suppl 1) 138-147
    CrossrefPubMedSearch in Google Scholar
  • 47 Pereyra Pacheco B, Méndez Ribas J M, Milone G et al.. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.  Gynecol Oncol. 2001;  81 (3) 391-397
    CrossrefPubMedSearch in Google Scholar
  • 48 Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy.  Eur J Gynaecol Oncol. 2004;  25 (1) 90-92
    PubMedSearch in Google Scholar
  • 49 Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study.  Anticancer Drugs. 2002;  13 (4) 417-424
    CrossrefPubMedSearch in Google Scholar
  • 50 Cumber P M, Whittaker J A. Ovarian failure after total body irradiation.  BMJ. 1990;  300 (6722) 464
    PubMedSearch in Google Scholar
  • 51 Kondo H, Searby N D, Mojarrab R et al.. Total-body irradiation of postpubertal mice with (137)Cs acutely compromises the microarchitecture of cancellous bone and increases osteoclasts.  Radiat Res. 2009;  171 (3) 283-289
    CrossrefPubMedSearch in Google Scholar
  • 52 Nakagawa K, Kanda Y, Yamashita H et al.. Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic SCT recipients undergoing TBI.  Bone Marrow Transplant. 2008;  42 (10) 697-699
    CrossrefPubMedSearch in Google Scholar
  • 53 Feng W, Cui Y, Zhan H et al.. Prevention of premature ovarian failure and osteoporosis induced by irradiation using allogeneic ovarian/bone marrow transplantation.  Transplantation. 2010;  89 (4) 395-401
    CrossrefPubMedSearch in Google Scholar
  • 54 Chao H T, Wang P H, Yuan C C, Lee W L. Successful pregnancy in a woman with acute myeloid leukemia treated with high-dose whole-body irradiation.  J Reprod Med. 1998;  43 (8) 703-706
    PubMedSearch in Google Scholar
  • 55 Jacob A, Goodman A, Holmes J. Fertility after bone marrow transplantation following conditioning with cyclophosphamide and total body irradiation.  Bone Marrow Transplant. 1995;  15 (3) 483-484
    PubMedSearch in Google Scholar
  • 56 Rahhal S N, Eugster E A. Unexpected recovery of ovarian function many years after bone marrow transplantation.  J Pediatr. 2008;  152 (2) 289-290
    CrossrefPubMedSearch in Google Scholar
  • 57 Samuelsson A, Fuchs T, Simonsson B, Björkholm M. Successful pregnancy in a 28-year-old patient autografted for acute lymphoblastic leukemia following myeloablative treatment including total body irradiation.  Bone Marrow Transplant. 1993;  12 (6) 659-660
    PubMedSearch in Google Scholar
  • 58 Bakker B, Massa G G, Oostdijk W, Van Weel-Sipman M H, Vossen J M, Wit J M. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies.  Eur J Pediatr. 2000;  159 (1-2) 31-37
    CrossrefPubMedSearch in Google Scholar
  • 59 Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood.  J Pediatr. 1997;  130 (2) 210-216
    CrossrefPubMedSearch in Google Scholar
  • 60 Castelo-Branco C, Rovira M, Pons F et al.. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation.  Maturitas. 1996;  23 (3) 307-312
    CrossrefPubMedSearch in Google Scholar
  • 61 Prince R L. Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis.  Endocr Rev. 1994;  15 (3) 301-309
    PubMedSearch in Google Scholar
  • 62 Rebar R W. Premature ovarian failure.  Obstet Gynecol. 2009;  113 (6) 1355-1363
    CrossrefPubMedSearch in Google Scholar
  • 63 Lissett C A, Shalet S M. The impact of dose and route of estrogen administration on the somatotropic axis in normal women.  J Clin Endocrinol Metab. 2003;  88 (10) 4668-4672
    CrossrefPubMedSearch in Google Scholar
  • 64 Mah P M, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M, Ross R J. Estrogen replacement in women of fertile years with hypopituitarism.  J Clin Endocrinol Metab. 2005;  90 (11) 5964-5969
    CrossrefPubMedSearch in Google Scholar
  • 65 Canonico M, Oger E, Plu-Bureau G Estrogen and Thromboembolism Risk (ESTHER) Study Group et al.. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.  Circulation. 2007;  115 (7) 840-845
    CrossrefPubMedSearch in Google Scholar
  • 66 Scarabin P Y, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group . Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.  Lancet. 2003;  362 (9382) 428-432
    CrossrefPubMedSearch in Google Scholar
  • 67 Popat V B, Vanderhoof V H, Calis K A, Troendle J F, Nelson L M. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency.  Fertil Steril. 2008;  89 (2) 429-433
    CrossrefPubMedSearch in Google Scholar
  • 68 Bjarnason K, Cerin A, Lindgren R, Weber T. Scandinavian Long Cycle Study Group . Adverse endometrial effects during long cycle hormone replacement therapy.  Maturitas. 1999;  32 (3) 161-170
    CrossrefPubMedSearch in Google Scholar
  • 69 Gibbons W E, Moyer D L, Lobo R A, Roy S, Mishell Jr D R. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women.  Am J Obstet Gynecol. 1986;  154 (2) 456-461
    PubMedSearch in Google Scholar
  • 70 DiVasta A D, Gordon C M. Hormone replacement therapy for the adolescent patient.  Ann N Y Acad Sci. 2008;  1135 204-211
    CrossrefPubMedSearch in Google Scholar
  • 71 Popat V B, Kalantaridou S, Reynolds J C et al.. Physiologic transdermal estradiol replacement therapy restores femoral neck bone density in women with spontaneous 46,XX primary ovarian insufficiency: 3 year randomized controlled clinical trial.  Fertil Steril. 2007;  88 S48
    PubMedSearch in Google Scholar
  • 72 Crofton P M, Evans N, Bath L E et al.. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover.  Clin Endocrinol (Oxf). 2010;  73 (6) 707-714
    CrossrefPubMedSearch in Google Scholar
  • 73 Saggese G, Baroncelli G I, Bertelloni S, Barsanti S. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.  J Clin Endocrinol Metab. 1996;  81 (8) 3077-3083
    CrossrefPubMedSearch in Google Scholar
  • 74 Ari M, Bakalov V K, Hill S, Bondy C A. The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner syndrome.  J Clin Endocrinol Metab. 2006;  91 (11) 4302-4305
    CrossrefPubMedSearch in Google Scholar
  • 75 Aycan Z, Cetinkaya E, Darendeliler F et al.. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.  Clin Endocrinol (Oxf). 2008;  68 (5) 769-772
    CrossrefPubMedSearch in Google Scholar
  • 76 Suganuma N, Furuhashi M, Hirooka T et al.. Bone mineral density in adult patients with Turner's syndrome: analyses of the effectiveness of GH and ovarian steroid hormone replacement therapies.  Endocr J. 2003;  50 (3) 263-269
    CrossrefPubMedSearch in Google Scholar
  • 77 Sass T C, De Muinck Keizer-Schrama S M, Stijnen T et al.. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial.  Clin Endocrinol (Oxf). 2000;  52 (5) 531-536
    CrossrefPubMedSearch in Google Scholar
  • 78 Hanton L, Axelrod L, Bakalov V, Bondy C A. The importance of estrogen replacement in young women with Turner syndrome.  J Womens Health (Larchmt). 2003;  12 (10) 971-977
    CrossrefPubMedSearch in Google Scholar
  • 79 Högler W, Briody J, Moore B, Garnett S, Lu P W, Cowell C T. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry.  J Clin Endocrinol Metab. 2004;  89 (1) 193-199
    CrossrefPubMedSearch in Google Scholar
  • 80 Khastgir G, Studd J W, Fox S W, Jones J, Alaghband-Zadeh J, Chow J W. A longitudinal study of the effect of subcutaneous estrogen replacement on bone in young women with Turner's syndrome.  J Bone Miner Res. 2003;  18 (5) 925-932
    CrossrefPubMedSearch in Google Scholar
  • 81 Grey A B, Stapleton J P, Evans M C, Tatnell M A, Ames R W, Reid I R. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women.  Am J Med. 1995;  99 (6) 636-641
    CrossrefPubMedSearch in Google Scholar
  • 82 Love R R, Mazess R B, Barden H S et al.. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.  N Engl J Med. 1992;  326 (13) 852-856
    CrossrefPubMedSearch in Google Scholar
  • 83 Resch A, Biber E, Seifert M, Resch H. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer.  Acta Oncol. 1998;  37 (7-8) 661-664
    CrossrefPubMedSearch in Google Scholar
  • 84 Delmas P D, Ensrud K E, Adachi J D Mulitple Outcomes of Raloxifene Evaluation Investigators et al.. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.  J Clin Endocrinol Metab. 2002;  87 (8) 3609-3617
    CrossrefPubMedSearch in Google Scholar
  • 85 Ettinger B, Black D M, Mitlak B H Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.  JAMA. 1999;  282 (7) 637-645
    CrossrefPubMedSearch in Google Scholar
  • 86 Ramaswamy B, Shapiro C L. Osteopenia and osteoporosis in women with breast cancer.  Semin Oncol. 2003;  30 (6) 763-775
    CrossrefPubMedSearch in Google Scholar
  • 87 Gnant M, Mlineritsch B, Luschin-Ebengreuth G Austrian Breast and Colorectal Cancer Study Group (ABCSG) et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.  Lancet Oncol. 2008;  9 (9) 840-849
    CrossrefPubMedSearch in Google Scholar
  • 88 Gnant M F, Mlineritsch B, Luschin-Ebengreuth G Austrian Breast and Colorectal Cancer Study Group et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.  J Clin Oncol. 2007;  25 (7) 820-828
    CrossrefPubMedSearch in Google Scholar
  • 89 Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.  Eur J Cancer. 2001;  37 (18) 2373-2378
    CrossrefPubMedSearch in Google Scholar

Madhusmita MisraM.D. M.P.H. 

BUL 457, Neuroendocrine Unit, Massachusetts General Hospital

55 Fruit Street, Boston, MA 02114

Email: mmisra@partners.org